Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 28/01/2022

    Artificial Muscles Made of Proteins

    Dr. Stefan Schiller and Dr. Matthias Huber from the University of Freiburg’s livMatS Cluster of Excellence have succeeded in developing a muscle solely on the basis of natural proteins. The autonomous contractions of the material, which the researchers presented in the journal Advanced Intelligent Systems, can be controlled with the help of pH and temperature changes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/artificial-muscles-made-proteins
  • Viral zoonoses - 24/01/2022 Schematic drawing of a flavivirus polyprotein anchored in the ER membrane. The different viral proteins are indicated by differently coloured sections on the polyprotein that is marked with dashes and the protease interfaces are marked by arrows.

    Development of inhibitors that help stop viral zoonoses

    Emerging viral infections such as COVID-19 or Zika disease pose an increasing threat to humans. At the Institute of Pharmacy and Molecular Biotechnology (IPMB) at Heidelberg University, Prof. Dr. Christian Klein's research group is developing inhibitors against already known viruses in the hope that these can also be used against new virus variants.

    https://www.gesundheitsindustrie-bw.de/en/article/news/development-inhibitors-help-stop-viral-zoonoses
  • microRNA as a prognostic biomarker - 13/01/2022 Screen of an ECG device showing the typical action potentials of the heart muscle.

    Heart attack diagnosis: fast and unambiguous thanks to artificial intelligence

    People that arrive in emergency rooms with chest pain require swift action in order to rule out a heart attack or to initiate vital life-saving therapy. However, despite many advances, current tests are not yet optimal: they either take hours or produce false-positive results. Researchers at Heidelberg University Hospital are now using AI in an approach that takes microRNAs from a blood sample to specifically diagnose ‘acute coronary syndrome’.

    https://www.gesundheitsindustrie-bw.de/en/article/news/heart-attack-diagnosis-fast-and-unambiguous-thanks-artificial-intelligence
  • Press release - 21/12/2021

    Cochlear implant as a sensor

    The cochlear implant (CI) is the most successful neural prosthesis worldwide. Thanks to direct stimulation of the auditory nerve, it enables more than half a million people worldwide to hear, even though those affected were born deaf or deafened.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cochlear-implant-sensor
  • Press release - 20/12/2021

    Immune microenvironment as a risk factor for colorectal cancer in Lynch syndrome

    Researchers at Heidelberg University Hospital (UKHD), the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have demonstrated for the first time that there is a link between the development of colorectal cancer in individuals with Lynch syndrome and the composition of immune cells in the colorectal mucosa.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-microenvironment-risk-factor-colorectal-cancer-lynch-syndrome
  • Press release - 18/12/2021

    WHO publishes first classification of childhood tumors

    The International Agency for Research on Cancer (IARC), an agency of the World Health Organization (WHO), will soon publish the first edition of its classification of childhood cancers. The new WHO classification forms the basis of modern, precise cancer diagnostics for physicians and pediatric oncologists worldwide and is based on the latest international research findings.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/who-publishes-first-classification-childhood-tumors
  • Press release - 09/12/2021

    New research project in mathematical oncology

    A new interdisciplinary research project aims to uncover information that can help decode hereditary colon cancer with the aid of mathematical models. Mathematicians and tumour biologists of Heidelberg University, the Heidelberg Institute for Theoretical Studies, Heidelberg University Hospital, and the German Cancer Research Center are collaborating on the project.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-research-project-mathematical-oncology
  • Press release - 07/12/2021

    New approach developed to predict response of immunotherapies in lung cancer

    At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-developed-predict-response-immunotherapies-lung-cancer
  • Gene regulation as a starting point for cancer therapies - 02/12/2021 Schematische Darstellung der verschiedenen Stadien der Genexpression. Nukleinsäurestränge sind durch farbige Linien, Proteine durch farbige Ellipsen und die Methylierung durch kleine Kreise dargestellt.

    New investigation method for deciphering complex epigenetic networks

    The development and maintenance of uncontrolled cell division in tumours is often due to the unbalanced, complex interplay of regulatory epigenetic networks. Researchers at the Institute of Biochemistry and Technical Biochemistry in Stuttgart have developed a new screening system to identify essential components that can serve as targets for anticancer drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-investigation-method-deciphering-complex-epigenetic-networks
  • Press release - 30/11/2021

    A mould dominates the eukaryotic microbiota in Parkinson’s disease patients

    Parkinson's disease is characterised by a slow, progressive loss of nerve cells in certain brain areas. The disease is still incurable and the exact causes are unclear. The dopamine deficiency in the brain can only be controlled to some extent in the initial phase of the disease. Basic research is being conducted in an attempt to unravel the mystery of Parkinson's disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mould-dominates-eukaryotic-microbiota-parkinsons-disease-patients
  • Press release - 29/11/2021

    Tracking down resistant cancer cells

    In multiple myeloma, a cancer of the bone marrow, relapse almost always occurs after treatment. Initially, most patients respond well to therapy. However, as the disease progresses, resistant cancer cells spread in the bone marrow, with fatal consequences for the patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracking-down-resistant-cancer-cells
  • Press release - 25/11/2021

    New Collaborative Research Centre at Ulm University Focusing on the factors that influence human aging

    After a highly competitive process Ulm University has been awarded its fifth Collaborative Research Centre (CRC). The new CRC 1506 ‘Aging at Interfaces’ addresses one of the most urgent medical challenges of our time: the aging of the human body and the diseases and constraints that are frequently associated with the aging process.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-collaborative-research-centre-ulm-university-focusing-factors-influence-human-aging
  • Press release - 23/11/2021

    Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response

    At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
  • Press release - 19/11/2021

    Keep an eye on us! – Bacteria on slit lamps

    Furtwangen University publishes the world’s first molecular biological study on bacterial contamination of slit lamps. Slit lamps are among the most important tools used by ophthalmologists and opticians. They allow selected areas of the eye to be magnified and examined for diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/keep-eye-us-bacteria-slit-lamps
  • Press release - 18/11/2021

    Overcoming resistance to treatment for breast, bowel, and pancreatic cancer

    As cancer progresses, the tumor cells continually change, ultimately resulting in a tumor consisting of a large number of different cell clones with different characteristics. This is referred to as "tumor heterogeneity". In many cases, the cancer cells become resistant to the treatments available.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-treatment-breast-bowel-and-pancreatic-cancer
  • Press release - 18/11/2021

    Overcoming resistance to cancer treatment: bone and soft tissue tumors in adolescents as a model system

    Treatment resistance is a central problem in the treatment of cancer. Bone and soft tissue tumors – known as sarcomas – in adolescents and young adults often stop responding to treatment too. This is because cancer cells develop a large number of new characteristics as the disease progresses and often become resistant to drugs that were originally effective.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-cancer-treatment-bone-and-soft-tissue-tumors-adolescents-model-system
  • Press release - 16/11/2021

    Cystic fibrosis & COPD: Mucus reprograms immune cells and promotes airway inflammation

    Scientists of the Translational Lung Research Center Heidelberg (TLRC) and the German Cancer Research Center (DKFZ) have discovered a new link between excessive airway mucus and chronic airway inflammation that is characteristic of cystic fibrosis and chronic obstructive pulmonary disease (COPD). The researchers showed that mucus in the airways reprograms certain cells of the immune system.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cystic-fibrosis-copd-mucus-reprograms-immune-cells-and-promotes-airway-inflammation
  • Press release - 15/11/2021

    Using T cell to target malignant brain tumors

    Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-t-cell-target-malignant-brain-tumors
  • Press release - 10/11/2021

    Plasticizers can cause asthma and allergies

    Plastic products can be found everywhere in daily life, soft plastic in particular often being used for packaging or children's toys. These often contain so-called plasticizers which ensure that the material remains flexible. Because plasticizers are not bonded permanently to the plastic, they can escape from the material, meaning they can be absorbed by humans.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/plasticizers-can-cause-asthma-and-allergies
  • Booster for neutrophil granulocytes - 27/10/2021 acetat-aktivierung_Bearbeitet.jpg

    Acetate supports immune cells to fight against sepsis

    Blood poisoning is the most dangerous complication of bacterial infections and often leads to death. Researchers at the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen have now identified acetate as a potent agent for stimulating innate immune system cells, supporting their ability to destroy bacteria.

    https://www.gesundheitsindustrie-bw.de/en/article/news/acetate-supports-immune-cells-fight-against-sepsis
  • Press release - 27/10/2021

    Disordered brain activity in Rolandic epilepsy can be influenced by brief sounds during sleep

    Rolandic epilepsy is a common form of epilepsy in children which occurs primarily during sleep. Short sounds played during sleep can partially suppress the neuronal discharges characteristic of epilepsy. That’s according to a research team from the University of Tübingen and Tübingen University Hospitals. The team is headed by Dr. Hong-Viet Ngo and Professor Jan Born from the Institute of Medical Psychology and Behavioral Neurobiology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/disordered-brain-activity-rolandic-epilepsy-can-be-influenced-brief-sounds-during-sleep
  • Press release - 25/10/2021

    How the "thermostat" in the brain measures impending overheating

    The mechanisms by which the body measures temperature and regulates its own body heat are vital, but still poorly understood. The discovery of the first heat sensor on nerve cells in the skin, for which the U.S. molecular biologist David Julius received this year's Nobel Prize for Medicine, was therefore pioneering.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-thermostat-brain-measures-impending-overheating
  • Press release - 19/10/2021

    Gips Schüle Research Award for three scientists from the University of Stuttgart

    Prof. Dr. Harald Gießen from the Institute of Physics (4) as well as Prof. Dr. Alois Herkommer and Dr. Simon Thiele from the Institute of Applied Optics at the University of Stuttgart received the Gips Schüle Research Award 2021 on October 19, 2021. The researchers were awarded the prize, which is valued at EUR 50,000.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/gips-schuele-research-award-three-scientists-university-stuttgart
  • Press release - 18/10/2021

    More precise characterization of brain tumors improves diagnosis and therapy

    An international study with about 3000 patients confirms the validity of a new classification system for meningiomas. It combines tissue characteristics (histology) with molecular analyses and thus improves therapy planning.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/more-precise-characterization-brain-tumors-improves-diagnosis-and-therapy
  • Press release - 13/10/2021

    Tackling the collateral damage from antibiotics

    EMBL scientists pave the way for reducing the harmful side effects antibiotics have on gut bacteria. Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body’s first lines of defence against pathogens and compromising the multiple beneficial effects our microbiota has for our health.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tackling-collateral-damage-antibiotics

Page 12 / 16

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search